07:00 , Sep 22, 2014 |  BioCentury  |  Finance

Caught short

Caught short Company Offering date Raised $M RA's net profit Halozyme Therapeutics Inc. (NASDAQ:HALO) 6/23/09 $40.0 $56,742 CTI Biopharma Corp. (NASDAQ:CTIC; Milan:CTIC) 7/23/09 $43.9 $312,125 Sangamo Biosciences Inc. (NASDAQ:SGMO) 10/7/09 $21.6 $23,200 Synta Pharmaceuticals Corp....
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

3Q14 Financial Markets Preview: Discerning optimism

Investors and bankers are cautiously optimistic that the correction that began in late 1Q14 will provide a floor for a biotech recovery that should continue through the third quarter, with investors being more selective on...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Financial News

BG Medicine completes follow-on

BG Medicine Inc. (NASDAQ: BGMD), Waltham, Mass.   Business: Diagnostic   Date completed: 4/3/14   Type: Follow-on   Raised: $10 million   Shares: 6.5 million   Price: $1.55   Shares after offering: 34.4 million  ...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Financial News

BG Medicine financial update

BG Medicine said it received notice from NASDAQ that it regained compliance with the $35 million minimum market value requirement for continued listing. BG Medicine Inc. (NASDAQ:BGMD), Waltham, Mass.   Business: Diagnostic   Date announced:...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Clinical News

BGM Galectin-3 test regulatory update

BG Medicine said the Centers for Medicare and Medicaid Services (CMS) issued a final decision to set the 2014 payment rate at $30.01 for its BGM Galectin-3 test, which is approved as an aid for...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

BGM Galectin-3 test regulatory update

BG Medicine said the Centers for Medicare and Medicaid Services (CMS) issued a preliminary decision to set the 2014 payment rate at $30.24 for its BGM Galectin-3 test as an aid for assessing the prognosis...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Company News

Acorda management update

Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y.   Business: Neurology, Musculoskeletal, Autoimmune   Hired: Michael Rogers as CFO, formerly EVP and CFO of BG Medicine Inc. ; he succeeds David Lawrence, who transitioned to CBO  ...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Financial News

BG Medicine financial update

BG Medicine received a letter from NASDAQ indicating that the company is not in compliance with the $1 minimum bid price requirement for continued listing. The company has until March 24, 2014, to regain compliance....
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

BG Medicine management update

BG Medicine Inc. (NASDAQ:BGMD), Waltham, Mass.   Business: Diagnostic, Proteomics, Supply/Service   Hired: Paul Sohmer as president, CEO and a director, formerly president and CEO of ViraCor-IBT Laboratories Inc. ; he replaces Eric Bouvier  ...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

ARCHITECT Galectin-3 test regulatory update

BG Medicine said partner Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.) received CE Mark approval for the ARCHITECT Galectin-3 test, an automated version of BG Medicine's BGM Galectin-3 test that is marketed as an aid in...